A Phase Ib Study of Pembrolizumab Following Trans-Arterial Chemoembolization in Primary Liver Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 12 Jun 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms PETAL
- 07 Jun 2019 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.
- 07 Jun 2019 Planned primary completion date changed from 31 Mar 2019 to 31 Mar 2020.
- 07 Aug 2018 Status changed from not yet recruiting to recruiting.